+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 16 Actively Recruiting clinical trials

S

Actively Recruiting

Researchers are evaluating the safety and effectiveness of a once-daily oral medication called AP1189, at a dose of 100 mg, compared to a placebo in participants who have respiratory insufficiency expected to be caused by respiratory viral infections such as SARS-CoV-2, Influenza A or B, or RSV. This study is a Phase 2, randomized, double-blind, placebo-controlled trial aiming to include 96 hospitalized participants. The goal is to assess AP1189 as an add-on treatment to the standard care provided for these respiratory infections. Participants will be randomly assigned in equal numbers to receive either AP1189 tablets or matching placebo tablets once daily for 14 days, alongside their standard of care treatment. The study monitors participants during this 14-day treatment period to evaluate treatment outcomes and safety. During the study, participants will be assessed for a composite outcome including death, need for invasive mechanical ventilation or ECMO, cardiovascular organ support, or new renal failure within 28 days. The study includes clinical evaluations, oxygen saturation measurements, and safety monitoring during and after treatment. Overall participation lasts at least 28 days to capture these outcomes and monitor participant health.

Age: 18Years +All GendersPhase 2
11 locations
P

Actively Recruiting

Researchers are evaluating the pharmacokinetics PK, safety, and tolerability of aumolertinib in European adults diagnosed with locally advanced or metastatic non-small cell lung cancer NSCLC that has specific activating mutations in the EGFR gene. This Phase 1, open-label, multicenter study focuses on participants whose tumors have mutations such as ex19del, L858R, or T790M. The goal is to better understand how aumolertinib and its metabolites behave in the body and their safety profile in this population. Participants receive aumolertinib orally at a dose of 110 mg once daily under fasting conditions in 21-day treatment cycles. The study has two parts Part A involves detailed PK assessments with visits for blood sampling on specific days within the first two treatment cycles to analyze drug levels. Part B allows participants to continue aumolertinib treatment beyond Cycle 2 until disease progression, intolerable side effects, or other discontinuation reasons determined by the investigator. During the study, participants will undergo safety evaluations and tumor assessments according to clinical needs. Blood samples for PK analysis are collected at multiple time points during the early treatment cycles. After stopping treatment, participants will have an End of Treatment visit within 7 days and a safety follow-up visit approximately 28 days after the last dose. The primary outcomes include measuring drug concentration peaks and exposure over 24 hours, while secondary outcomes focus on adverse events throughout the study, which may last about 18 months on average.

Age: 18Years +All GendersPhase 1
6 locations
P

Actively Recruiting

Researchers are evaluating the safety, tolerability, early clinical effects, and how the body processes azenosertib ZN-c3 when combined with other drugs in patients with advanced ovarian, peritoneal, or fallopian tube cancer. This Phase 1b open-label study includes patients with platinum-resistant or maintenance therapy contexts, aiming to understand dosing and treatment combinations better. The study has two parts Part 1 assessed azenosertib with chemotherapy drugs including carboplatin, pegylated liposomal doxorubicin PLD, paclitaxel, and gemcitabine in platinum-resistant cases. Part 2 explores azenosertib with bevacizumab as first- or second-line maintenance therapy after platinum chemotherapy. Dose escalation and expansion phases determine recommended doses and evaluate safety. Participants will receive study treatments in combination regimens and undergo regular assessments over about one year. Researchers monitor safety, side effects, and drug levels, aiming to find the maximum tolerated dose and recommended dosing. The study includes clinical evaluations, laboratory tests, and ongoing monitoring of patient response and tolerability throughout the study period.

Age: 18Years +FEMALEPhase 1
24 locations
E

Actively Recruiting

Researchers are evaluating the safety and effectiveness of several investigational long-acting antibody treatments, both alone and in combination, for adults with moderately to severely active ulcerative colitis UC. This Phase 2 platform study involves multiple centers and aims to improve treatment options for this condition by comparing different therapies. The study consists of two parts. Part A was an open-label phase assessing safety and early effectiveness of three monotherapies, which completed enrollment in April 2026. Part B is currently enrolling and is a randomized, placebo-controlled phase testing three monotherapies and three combination therapies against placebo. Participants will receive intravenous induction and subcutaneous maintenance treatments, with different dosing regimens evaluated over time. Participants will be monitored through regular assessments including endoscopy and histology to measure disease activity and response. The main outcomes include clinical remission and histologic improvement after 12 weeks, with longer-term remission assessed up to 48 weeks. Safety and efficacy data will be collected throughout, with treatment duration and follow-up determined by study protocol. The total study completion is expected by March 2028.

Age: 18Years - 75YearsAll GendersPhase 2
276 locations
R

Actively Recruiting

Researchers are evaluating the effects of biweekly XEMBIFY combined with Standard Medical Treatment SMT over one year in adults with hypogammaglobulinemia HGG who have B-cell Chronic Lymphocytic Leukemia CLL, Multiple Myeloma MM, or Non-Hodgkin Lymphoma NHL. The study aims to determine if this combination reduces the yearly rate of major bacterial infections compared to a placebo plus SMT. This Phase 3 trial is randomized, double-blinded, and placebo-controlled to ensure reliable results. Participants will receive either XEMBIFY or a placebo via subcutaneous infusion. The treatment starts with a loading dose of 150 mgkgday given daily for five days in the first week, followed by biweekly infusions of 300 mgkg from Week 3 through Week 51. Along with the study drug or placebo, all participants will continue to receive their usual standard medical treatments and supportive care needed during the trial. During the study, participants will be regularly monitored to assess the rate and timing of major bacterial infections and other infection-related outcomes. Researchers will track hospitalizations, antibiotic use, and overall infection rates up to Week 51. Safety and pharmacokinetics of the treatment will also be evaluated throughout. The total participation period lasts about one year, during which participants will have scheduled visits for treatment administration and assessments.

Age: 18Years +All GendersPhase 3
62 locations
P

Actively Recruiting

Researchers are studying the pharmacokinetics PK and safety of ublituximab given as a subcutaneous SC injection in people with relapsing multiple sclerosis MS. The study evaluates how the drug behaves in the body when injected at different sites and compares the bioavailability when administered by a prefilled pen versus a syringe. This Phase 2 trial is focused on treatment and aims to understand the best method of delivering ublituximab subcutaneously. Participants will receive ublituximab SC either at one of three different injection sites using a syringe or via a prefilled pen. The study randomly assigns participants to receive the drug using either the prefilled pen or the syringe. The treatment period includes assessments up to 12 weeks for primary PK measures and up to 120 weeks for safety and plasma concentration monitoring. During the study, participants will have blood samples taken to measure drug levels and safety will be monitored by tracking any adverse events. They will also report their satisfaction with the injection method through questionnaires up to week 96. The main outcome measured is the area under the curve AUC of ublituximab at steady state by week 12, with longer follow-up to assess plasma concentrations and side effects. The total study duration extends up to nearly three years, ensuring extended safety and treatment evaluation.

Age: 18Years - 65YearsAll GendersPhase 2
44 locations
O

Actively Recruiting

Researchers are evaluating the safety, tolerability, and activity of SAR448501DR-0201, a bispecific antibody, in adults with select autoimmune rheumatic diseases including systemic lupus erythematosus SLE and rheumatoid arthritis RA. This open-label, phase 1 study aims to find optimal doses by assessing pharmacokinetics, pharmacodynamics, immunogenicity, and preliminary clinical response. Participants will receive SAR448501 over a treatment period lasting up to 71 days, with multiple ascending dose levels studied across different cohorts. The study includes a screening period of up to 28 days before treatment and a follow-up period lasting 42 weeks after treatment ends. If needed, participants will continue to have visits every 4 weeks after the study until specific blood cell levels return to a set threshold. During the study, participants will undergo evaluations of adverse events and clinical responses up to 52 weeks. Researchers will measure drug levels in the blood, immune reactions, and disease activity markers. Safety monitoring includes ongoing assessments during treatment and follow-up, with a total participation time of about 13 months.

Age: 18Years - 75YearsAll GendersPhase 1
8 locations
O

Actively Recruiting

This observational study focuses on patients with nonvalvular atrial fibrillation who are receiving anticoagulant prophylaxis with apixaban. The research aims to evaluate the safety of apixaban by tracking the incidence of major bleeding and clinically relevant non-major bleeding, therapy adherence, and other adverse reactions excluding bleeding. The study is sponsored by Bosnalijek D.D and follows participants over six months to gather comprehensive safety and adherence data. Participants will take apixaban orally, with a standard dose of 5 mg twice daily or a reduced dose of 2.5 mg twice daily for those aged 80 or older, weighing 60 kg or less, or with specific serum creatinine levels. The study involves four measurements over six months the first and last are in-person, while the middle two can be done by telephone if needed. Immediate reporting of any bleeding or serious adverse reactions is required through unscheduled visits. During the six-month follow-up, researchers will collect data on bleeding events, adverse reactions, and medication adherence using the BARS scale. Participants will undergo scheduled assessments at four time points, and any serious side effects will be promptly recorded. The primary outcome is the combined incidence of major and clinically relevant non-major bleeding. Secondary outcomes include adherence rates, overall bleeding events, and other adverse reactions during this period.

Age: 18Years +All Genders
1 location
E

Actively Recruiting

Researchers are evaluating the efficacy and safety of Imeroprubart in adults with active Chronic Inflammatory Demyelinating Polyneuropathy CIDP, a neurological disorder. This Phase 2b, multi-center, randomized, double-blind, placebo-controlled study focuses on adult participants who meet specific diagnostic criteria for CIDP or its variants. The study is sponsored by Immunovant Sciences GmbH and aims to understand how well Imeroprubart helps prevent relapses and improves disability and muscle strength in this population. Participants will receive either Imeroprubart or a matching placebo by subcutaneous injection once weekly. The initial treatment period lasts 24 weeks, with a further extension period of 52 weeks for continued evaluation. Imeroprubart is given as a dose 1 injection under the skin weekly during these periods, while the placebo group receives matching injections during the first 24 weeks. Throughout the study, participants will be regularly assessed for relapse status, disability scales, grip strength, muscle strength scores, and functional impairment from baseline up to Week 24. These assessments include standardized clinical scales such as the Inflammatory Rasch-Built Overall Disability Scale I-RODS and Medical Research Council Sum Score MRC-SS. Safety and efficacy are closely monitored, with the primary outcome focusing on the proportion of participants remaining relapse-free by Week 24. The total study duration extends until May 2030.

Age: 18Years +All GendersPhase 2
142 locations
P

Actively Recruiting

Researchers are studying advanced hepatocellular carcinoma HCC in patients who have Child-Pugh Class B7 cirrhosis and whose cancer has worsened after at least one prior treatment. This clinical trial aims to compare the safety and effectiveness of the drug namodenoson with a placebo in this group of patients. The trial is a Phase 3, multicenter, randomized, double-blind study designed to provide clear evidence on the benefits and risks of namodenoson for this condition. Participants will be randomly assigned to receive either namodenoson 25 mg or a matching placebo by mouth twice daily in 28-day cycles. Treatment continues until the disease progresses or side effects become unacceptable. Tumor imaging is performed every two cycles to monitor disease status. After stopping the study drug, patients will have a follow-up visit 28 days later, and those who agree will be monitored long-term for survival. If results allow, some patients may continue taking namodenoson openly beyond the blinded phase. During the study, participants will regularly visit the clinic for safety checks, laboratory tests, and tumor imaging. The main outcome measured is overall survival up to 60 months after randomization. Secondary outcomes include progression-free survival, objective response rate, and the nature of side effects. Pharmacokinetics of namodenoson will also be studied. Long-term survival data will be collected for those who consent to follow-up, ensuring thorough monitoring throughout the study period.

Age: 18Years +All GendersPhase 3
32 locations

1-10 of 16

1